Albumin-Adjusted Serum Calcium Levels Higher with Tumor Malignancy
the Cancer Therapy Advisor take:
Albumin-adjusted serum calcium was reported to be significantly greater in women with malignant tumors, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
Participants in this study included 514 women who underwent resection at Wake Forest University Baptist Medical Center (July 2009-June 2013) for pelvic masses. The patients were divided into a “training” set and a “testing” set (to identify data associations and to provide confirmation of these associations, respectively).
Results showed women with malignant masses had significantly greater levels of albumin-adjusted serum calcium levels compared to those with benign masses (P=0.0004).
High normocalcemia (ie, an albumin-adjusted serum calcium ≥10 mg/dL) was reported in 53% of women with malignant tumors compared with 12% in those with benign tumors. Furthermore, the high normocalcemia correlated to an increased risk of malignancy of approximately 14-fold.
The study suggests serum albumin and calcium could be an economic and sensitive method to predict malignancy of tumors in women with pelvic masses.
Albumin-adjusted serum calcium was reported to be significantly greater in women with malignant tumors.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC